AI software mapping during ablation for persistent atrial fibrillation
Tests whether AI mapping predicts return of irregular heartbeat after ablation in adults.
Plain-language title generated from the registry record
Registry title: Use of Volta Medical AI-software During Atrial Fibrillation Ablation to Identify Patients Who May Need More Than Pulmonary Vein Isolation.
Key facts
- Where
- Avignon, Bron, Dijon, Marseille, and Strasbourg, FranceSee the 5 sites
Where in France
- Clinique Rhône DuranceAvignon, FranceNot yet recruiting
- Hôpital Cardiologique Louis Pradel - HCLBron, FranceNot yet recruiting
- CHU DijonDijon, FranceNot yet recruiting
- Hôpital Saint Joseph MarseilleMarseille, FranceTaking people
- Clinique RhénaStrasbourg, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Volta Medical
- Trial code
- NCT07807423
- Record updated
- 25 September 2026
- Original description
DISPLAY-AF is a prospective, multicenter, single-arm post-market clinical follow-up investigation designed to evaluate whether spatiotemporal dispersion areas identified by the Volta AF-Xplorer II artificial intelligence (AI) software can predict recurrence of atrial arrhythmias after pulmonary vein isolation (PVI)-only ablation in patients with persistent atrial fibrillation.Read full original descriptionShow less
Relationship Between Spatiotemporal Dispersion Areas DISPLAYed by Volta Medical Artificial Intelligence Software and Atrial Arrhythmia Recurrence After Pulmonary Vein Isolation-Only Ablation for Persistent Atrial Fibrillation
DISPLAY-AF is a prospective, multicenter, single-arm post-market clinical follow-up investigation designed to evaluate whether spatiotemporal dispersion areas identified by the Volta AF-Xplorer II artificial intelligence (AI) software can predict recurrence of atrial arrhythmias after pulmonary vein isolation (PVI)-only ablation in patients with persistent atrial fibrillation.
Inclusion: Patient aged 18 years or older; De novo patient candidate for catheter ablation of persistent atrial fibrillation (AF episode >7 days); Continuous anticoagulation for more than 4 weeks before ablation; Patient giving his signed consent form to participate in the clinical study; Patient affiliated to the French social security.
Exclusion: Contraindication to anticoagulation (Heparin, Warfarin or NOAC…) or lack of anticoagulation for 4 weeks prior to the procedure; Presence of a LA thrombus on transesophageal echocardiography (TEE) prior to the procedure; Major bleeding disorder; History of blood clotting or bleeding abnormalities; Acute illness or active systemic infection or sepsis; Any cardiac surgery within the past 2 months (60 days) (includes PCI); Myocardial infarction within the past 2 months (60 days); Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days); Presence of intramural thrombus, tumor or other abnormality or condition that precludes vascular access, or manipulation of the catheter; Unstable angina within the past month; Significant severe pulmonary disease, (e.g. patients with restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease in GOLD stage IV) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms (e.g. unstable or untreated sleep apnea); Contraindication to AF/AT catheter ablation; Diagnosed atrial myxoma; Documented thromboembolic event (including TIA) within the past 12 months (365 days); Patient who is or could potentially be pregnant; Person deprived of liberty or under guardianship; Patient's refusal to participate in the study.